MULTIPLE MYELOMA. STUDIES OF MOUSE PLASMA CELL TUMOR AND HUMAN MYELOMA RESPONSIVENESS TO CYCLOPHOSPHAMIDE (CYTOXAN).

No abstract is available for this paper.

• Publication year

  1964

• Venue

  Annals of Internal Medicine

• Publication date

  1964-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-60-2-217PMID 14114442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Hormones on Advanced Breast Cancer: A Five-year Study.

  1962cited by this paper
• Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).

  1962cited by this paper
• Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. 1-Aminocyclopentanecarboxylic acid (NSC-1026).

  1962cited by this paper
• Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. I. Plan of study.

  1962cited by this paper
• Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.

  1962cited by this paper
• A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma.

  1962cited by this paper
• A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma.

  1962cited by this paper
• Disturbances of Gamma Globulin Synthesis.

  1962cited by this paper
• Effects of heterologous transplantation of a mouse plasmacytoma. I. Runting syndrome secondary to malignant tumors.

  1962cited by this paper
• Hypergammaglobulinemia in Mink.∗

  1961cited by this paper
• A comparative study of optimal medical care with and without azaserine in multiple myeloma

  1961cited by this paper
• Cyclophosphamide therapy. Its use in leukemia, lymphoma and solid tumors.

  1961cited by this paper
• The effect of 1-aminocyclopentane carboxylic acid (NSC-1026) on mouse plasmacytoma.

  1961cited by this paper
• "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases.

  1961cited by this paper
• A method for demonstrating probable synthesis of protein by bone marrow cells.

  1961cited by this paper
• Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.

  1961cited by this paper
• The effect of 1-aminocyclopentane carboxylic acid (NSC-1026) on mouse plasmacytoma.

  1961cited by this paper
• A study on globulin formation by plasma-cell neoplasm (5563) transplantable in mice.

  1961cited by this paper
• Some ultrastructural characteristics of a series of primary and transplanted plasma-cell tumors of the mouse.

  1961cited by this paper
• Continuous chlorambucil therapy in primary macroglobulinemia of Waldenstrom: report of four cases.

  1961cited by this paper
• Cyclophosphamide in Hodgkin's Disease and Related Disorders

  1960cited by this paper
• Duration of survival in multiple myeloma.

  1960cited by this paper
• The survival time of patients with plasmocytic myeloma.

  1960cited by this paper
• A prelusive clinical trial of cyclophosphamide.

  1960cited by this paper
• Cyclophosphamide. A preliminary study of a new alkylating agent.

  1960cited by this paper
• The survival time of patients with plasmocytic myeloma.

  1960cited by this paper
• A prelusive clinical trial of cyclophosphamide.

  1960cited by this paper
• Some effects of cyclophosphamide (cytoxan) on normal mice and mice with L1210 leukemia.

  1959cited by this paper
• “MYELOMA” SERUM ELECTROPHORETIC PATTERNS IN CONDITIONS OTHER THAN MYELOMATOSIS

  1959cited by this paper
• Plasma-cell myeloma. II. Clinical aspects.

  1959cited by this paper
• Alterations of Gamma Globulin with Plasma Cell Neoplasm in Mice.∗

  1959cited by this paper
• Immunocytochemical study of plasma cells in multiple myeloma.

  1958cited by this paper
• [First experience in treating malignant tumors with a new nitrogen mustard-phosphamidester].

  1958cited by this paper
• The use of serum protein electrophoresis in clinical medicine.

  1958cited by this paper
• THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMOR

  1958cited by this paper
• The management of multiple myeloma.

  1957cited by this paper
• Abnormal Serum Protein and Bone Destruction in Transmissible Mouse Plasma Cell Neoplasm (Multiple Myeloma)

  1957cited by this paper
• Studies of a plasma-cell neoplasm of the mouse. I. Characterization of neoplasm 70429, including its sensitivity to various antimetabolites with the rapid development of resistance to azaserine, DON, and N-methylformamide.

  1957cited by this paper
• The metabolism of a therapeutic dose of 45Ca in a case of multiple myeloma.

  1956cited by this paper
• Long-term survival in multiple myeloma: report of three cases.

  1956cited by this paper
• Plasma cell myeloma; a clinical, pathologic and roentgenologic review of 90 cases.

  1955cited by this paper
• Treatment of multiple myeloma with radioactive iodine and radioactive iodinated serum albumin.

  1955cited by this paper
• Observations on the formation and nature of Russell bodies.

  1954cited by this paper
• An electrophoretic study on the origin of the abnormal plasma proteins in multiple myeloma.

  1952cited by this paper
• Plasmacytoma of the mandible.

  1952cited by this paper
• Urethane in multiple myeloma. I. Final report of a case treated more than four years with urethane.

  1952cited by this paper
• Abnormal proteins in myeloma.

  1952cited by this paper
• TREATMENT OF MULTIPLE MYELOMA WITH URETHAN: EXPERIENCE WITH SIXTY-SIX CASES OVER A TWO-AND-A-HALF-YEAR PERIOD

  1951cited by this paper
• Treatment of multiple myeloma with urethan; experience with 66 cases over a 2 1/2 year period.

  1951cited by this paper
• The treatment of multiple myelomata with radioactive phosphorus.

  1951cited by this paper
• Multiple Myeloma

  1950cited by this paper
• Multiple myeloma; a study of 24 patients treated with radioactive isotopes (P32 and SR89).

  1950cited by this paper
• Urethane in the treatment of multiple myeloma.

  1950cited by this paper
• The treatment of multiple myeloma with urethane

  1950cited by this paper
• Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence Jones proteinuria.

  1950cited by this paper
• Multiple myeloma; its clinical and laboratory diagnosis with emphasis on electrophoretic abnormalities.

  1949cited by this paper
• Unusual remission after radiophosphorus therapy in a case of acute plasma cell leukemia.

  1948cited by this paper
• Roentgen treatment of multiple myeloma.

  1948cited by this paper
• Urethane and stilbamidine in multiple myeloma report on two cases.

  1947cited by this paper
• Multiple myeloma; a review of 83 proved cases.

  1947cited by this paper
• MULTIPLE MYELOMA: A Review of Eighty-Three Proved Cases

  1947cited by this paper
• Radioactive phosphorus as a therapuetic agent; a review of the literature and analysis of the results of treatment of 155 patients with various blood dyscrasias, lymphomas, and other malignant neoplastic diseases.

  1946cited by this paper

• Zur Lebenserwartung unbehandelter und behandelter Plasmozytomkranker

  2005cites this paper
• Klinische Aspekte der Chemotherapie bösartiger Tumoren und maligner Systemerkrankungen

  2004cites this paper
• Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse.

  1995cites this paper
• A plasma clot culture system for growing and antiproliferative drug sensitivity testing of myeloma stem cells.

  1984cites this paper
• The treatment of multiple myeloma.

  1973cites this paper
• Melphalan and prednisone: An effective combination for the treatment of multiple myeloma

  1973cites this paper
• Serum ribonuclease in multiple myeloma.

  1971cites this paper
• Monoclonal gammopathy with hyperlipidemia.

  1970cites this paper
• Die therapie der Paraproteinämien

  1969cites this paper
• [Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride].

  1969cites this paper
• [The therapy of the paraproteinemias].

  1969cites this paper
• Behandlung des multiplen Myeloms mit einem neuen Zytostatikum

  1969cites this paper
• [Apropos of 10 cases of multiple myeloma treated with 1-sarcolysine].

  1968cites this paper
• Melphalan in multiple myeloma.

  1967cites this paper
• [Therapy of plasmocytoma].

  1967cites this paper
• Cyclophosphamide in the treatment of myelomatosis.

  1967cites this paper
• [Life prognosis of treated and non-treated patients with plasmacytoma].

  1967cites this paper
• Treatment of tumors of the hematopoietic system.

  1966cites this paper
• [Clinical aspects of chemotherapy of malignant tumors and malignant systemic diseases].

  1966cites this paper
• Clinical and metabolic investigations of eight cases of multiple myeloma during prolonged cyclophosphamide administration

  1966cites this paper
• AGGREGATION OF IGG GLOBULIN IN VIVO. I. THE HYPERVISCOSITY SYNDROME IN MULTIPLE MYELOMA.

  1965cites this paper
• MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.

  1964cites this paper
• SCIENTIFIC METHODOLOGY IN CLINICAL MEDICINE. 3. THE EVALUATION OF THERAPEUTIC RESPONSE.

  1964cites this paper